Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.52 |
| ▸ | LTA4H | P09960 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7087531 | 0.85 | ACE (0.56) | ACELTA4HLMNAACE2 | |
| SCHEMBL29290359 | 0.85 | ACE (0.56) | ACELTA4HLMNAACE2 | |
| SCHEMBL13923719 | 0.82 | ACE (0.63) | ACELTA4HLMNAACE2SMN1; SMN2 | |
| SCHEMBL27890164 | 0.81 | ACE (0.73) | ACELTA4HLMNAACE2 | |
| SCHEMBL27890165 | 0.81 | ACE (0.73) | ACELTA4HLMNAACE2 | |
| SCHEMBL6436563 | 0.80 | ACE (0.65) | ACELTA4HLMNAACE2SMN1; SMN2 | |
| SCHEMBL6438293 | 0.80 | ACE (0.65) | ACELTA4HLMNAACE2SMN1; SMN2 | |
| SCHEMBL6438290 | 0.80 | ACE (0.65) | ACELTA4HLMNAACE2SMN1; SMN2 | |
| SCHEMBL6436560 | 0.80 | ACE (0.65) | ACELTA4HLMNAACE2SMN1; SMN2 | |
| SCHEMBL13942467 | 0.80 | ACE (0.43) | ACELTA4HLMNAACE2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013170-B2 | Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage | NEUREN PHARMACEUTICALS LIMITED (AU) | 2011-09-06 | — | — | US | disclosed |
| US-20110052528-A1 | Neuroprotective macrocyclic compounds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052528-A1 | Neuroprotective macrocyclic compounds and methods for their use | NLN, BAD, BDNF | ACE 1715/4885LTA4H 3453/4885LMNA 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.